Serving leading biopharmaceutical companies globally:
Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing
Serving leading biopharmaceutical companies globally:
Generated: October 18, 2017
What is the competitive landscape for IRONWOOD PHARMS INC, and when can generic versions of IRONWOOD PHARMS INC drugs launch?
IRONWOOD PHARMS INC has two approved drugs.| International Patents: | 161 |
| US Patents: | 7 |
| Tradenames: | 2 |
| Ingredients: | 2 |
| NDAs: | 2 |
Export unavailable in trial.
Subscribe for complete access.
For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.
The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.
| Patent No. | Title | Estimated Patent Expiration | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 8,252,828 | S-triazolyl .alpha.-mercapto acetanilides as inhibitors of HIV reverse transcriptase | ► Subscribe | |||||||||||||
| 8,633,232 | Compounds, compositions and methods of using same for modulating uric acid levels | ► Subscribe | |||||||||||||
| 7,435,752 | N[S(4-aryl-triazol-3-yl).alpha.-mercaptoacetyl]-p-amino benozioc acids as HIV reverse transcriptase inhibitors | ► Subscribe | |||||||||||||
| 8,946,273 | S-Triazolyl alpha-mercapto acetanilides as inhibitors of HIV reverse transcriptase | ► Subscribe | |||||||||||||
| 8,173,690 | Compounds, compositions and methods of using same for modulating uric acid levels | ► Subscribe | |||||||||||||
| 7,947,721 | S-triazolyl .alpha.-mercaptoacetanilides as inhibitors of HIV reverse transcriptase | ► Subscribe | |||||||||||||
| 8,344,012 | Compounds, compositions and methods of using same for modulating uric acid levels | ► Subscribe | |||||||||||||
| 8,106,205 | N[S(4-aryl-triazol-3-yl).alpha.-mercaptoacetyl]p-amino benzoic acids as HIV reverse transcriptase inhibitors | ► Subscribe | |||||||||||||
| 8,481,581 | S-triazolyl .alpha.-mercaptoacetanilides as inhibitors of HIV reverse transcriptase | ► Subscribe | |||||||||||||
| 7,683,087 | N[S(4-aryl-triazol-3-yl).alpha.-mercaptoacetyl] -p-amino benzoic acids as HIV reverse transcriptase inhibitors | ► Subscribe | |||||||||||||
| This preview shows a limited data set Subscribe for full access, or try a Trial | |||||||||||||||
The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.
Export unavailable in trial.
Subscribe for complete access.
| Country | Document Number | Estimated Expiration | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ecuador | SP10010310 | ► Subscribe | |||||||||||||
| World Intellectual Property Organization (WIPO) | 2010028189 | ► Subscribe | |||||||||||||
| Denmark | 2658846 | ► Subscribe | |||||||||||||
| Brazil | PI0514630 | ► Subscribe | |||||||||||||
| Eurasian Patent Organization | 201100441 | ► Subscribe | |||||||||||||
| South Africa | 201204031 | ► Subscribe | |||||||||||||
| European Patent Office | 2135608 | ► Subscribe | |||||||||||||
| Mexico | 2013007505 | ► Subscribe | |||||||||||||
| Spain | 2614914 | ► Subscribe | |||||||||||||
| Lithuania | 2658846 | ► Subscribe | |||||||||||||
| This preview shows a limited data set Subscribe for full access, or try a Trial | |||||||||||||||
The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws,
it is advisable to have patent counsel verify freedom to operate.
Export unavailable in trial.
Subscribe for complete access.
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 90033-4 | Sweden | ► Subscribe | PRODUCT NAME: LESINURAD, OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF.; REG. NO/DATE: EU/1/15/1080 20160222 | ||||||||||||
| /2016 | Austria | ► Subscribe | PRODUCT NAME: LESINURAD ODER EIN PHARMAZEUTISCH VERTRAEGLICHES SALZ DAVON; REGISTRATION NO/DATE: EU/1/15/1080 (MITTEILUNG) 20160222 | ||||||||||||
| 2016024 | Lithuania | ► Subscribe | PRODUCT NAME: LESINURADAS; REGISTRATION NO/DATE: EU/1/15/1080 20160218 | ||||||||||||
| C0031 | France | ► Subscribe | PRODUCT NAME: LESINURAD; REGISTRATION NO/DATE: EU/1/15/1080 20160222 | ||||||||||||
| 2016000060 | Germany | ► Subscribe | PRODUCT NAME: LESINURAD ODER EIN PHARMAZEUTISCH VERTRAEGLICHES SALZ DAVON; REGISTRATION NO/DATE: EU/1/15/1080 20160218 | ||||||||||||
| 169 | Luxembourg | ► Subscribe | PRODUCT NAME: LESINURAD , OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI; FIRST REGISTRATION DATE: 20160222 | ||||||||||||
| 2016 00034 | Denmark | ► Subscribe | PRODUCT NAME: LESINURAD ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF; REG. NO/DATE: EU1/15/1080 20160222 | ||||||||||||
| 0825 | Netherlands | ► Subscribe | PRODUCT NAME: LESINURAD; REGISTRATION NO/DATE: EU/1/15/1080 20160222 | ||||||||||||
| 2016024,C2135608 | Lithuania | ► Subscribe | PRODUCT NAME: LESINURADAS ARBA JO FARMACINIU POZIURIU PRIIMTINA DRUSKA; REGISTRATION NO/DATE: EU/1/15/1080 20160218 | ||||||||||||
| 0160027 00203 | Estonia | ► Subscribe | PRODUCT NAME: LESINURAAD;REG NO/DATE: EU/1/15/1080 22.02.2016 | ||||||||||||
| This preview shows a limited data set Subscribe for full access, or try a Trial | |||||||||||||||
Export unavailable in trial.
Subscribe for complete access.
Serving leading biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Follow DrugPatentWatch:
Join the 22,926 others who get our Drug Patent Expiration Alerts:
